Lebrikizumab Dosed Every 8 Weeks As Maintenance Provides Long-Lasting Response in Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin 2025, 9 (6), s601. https://doi.org/10.25251/14pn6v71.